Histone deacetylases mRNA profile in mesenchymal stem cells derived from ovariectomized mice

doi:10.3969/j.issn.2095-4344.2014.10.007

Abstract

Abstract:

BACKGROUND: As the multipotent differentiation potential, bone marrow mesenchymal stem cells exert an important role in bone metabolism disorders, which is regulated by a variety of hormones and cytokines. Currently, the epigenetic regulatory mechanisms underlying osteogenic differentiation of bone marrow mesenchymal stem cells are unclear, and association between histone deacetylase (Hdac) and osteoporosis needs to be further explored.
OBJECTIVE: To investigate the epigenetic mechanisms of bone formation by analyzing the expression of Hdac1, 3, 4 mRNA profile in bone marrow mesenchymal stem cells isolated from ovariectomized mice.
METHODS: A total 30 female healthy Kunming mice were randomly divided into sham group and ovariectomy group. After 7 days of adaptive feeding, mice in the ovariectomized group (n=15) were subject to bilateral ovariectomy; mice in sham group (n=15) were sham-operated.
RESULTS AND CONCLUSION: In the ovariectomy group, the trabecular bone of the femur was sparse or broken, the width of trabecular bone was narrowed, the trabecular separation was widened, and the trabecular bone volume was reduced. The level of Hdac3 mRNA was lower in bone marrow mesenchymal stem cells from ovariectomized mice compared with controls, but there was no significance between Hdac1, Hdac4 mRNA expression of the two groups. These findings demonstrate that Hdac might play an important role in bone remodeling in the model of estrogen deficiency-induced osteoporosis.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: cell differentiation, mesenchymal stem cells, ovariectomy, osteoporosis

CLC Number:

R394.2

Liu Da-yong, Tai Yong, Wang Mei-rui, Cui Ting, Liu Ping, Zhao Meng-ming, Jia Zhi. Histone deacetylases mRNA profile in mesenchymal stem cells derived from ovariectomized mice[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(10): 1514-1520.

Figures/Tables 4

References

[1]Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009;5(1):20-27.

[2]Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423(6937):349-355.

[3]Gao Y, Yang G, Weng T, et al. Disruption of Smad4 in odontoblasts causes multiple keratocystic odontogenic tumors and tooth malformation in mice. Mol Cell Biol. 2009; 29(21):5941-5951.

[4]Ho JH, Ma WH, Su Y, et al. Thymosin beta-4 directs cell fate determination of human mesenchymal stem cells through biophysical effects. J Orthop Res. 2010;28(1):131-138.

[5]Leskelä HV, Olkku A, Lehtonen S, et al. Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem -cell-derived osteoblasts. Bone. 2006;39(5):1026-1034.

[6]Liu Y, Wang L, Kikuiri T, et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med. 2011;17(12):1594-1601.

[7]Scheller EL, Song J, Dishowitz MI, et al. Leptin functions peripherally to regulate differentiation of mesenchymal progenitor cells. Stem Cells. 2010;28(6):1071-1080.

[8]Zhang X, Yang M, Lin L, et al. Runx2 overexpression enhances osteoblastic differentiation and mineralization in adipose--derived stem cells in vitro and in vivo. Calcif Tissue Int. 2006;79(3):169-178.

[9]Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999;286(5439):481-486.

[10]Calarco JP, Borges F, Donoghue MT, et al. Reprogramming of DNA methylation in pollen guides epigenetic inheritance via small RNA. Cell. 2012;151(1):194-205.

[11]Du J, Zhong X, Bernatavichute YV, et al. Dual binding of chromomethylase domains to H3K9me2-containing nucleosomes directs DNA methylation in plants. Cell. 2012; 151(1):167-180.

[12]Johnson LM, Du J, Hale CJ, et al. SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature. 2014. in press.

[13]Xie W, Barr CL, Kim A, et al. Base-resolution analyses of sequence and parent-of-origin dependent DNA methylation in the mouse genome. Cell. 2012;148(4):816-831.

[14]Black JC, Manning AL, Van Rechem C, et al. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell. 2013;154(3):541-555.

[15]Liu W, Ma Q, Wong K, et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell. 2013;155(7):1581-1595.

[16]Lyons DB, Allen WE, Goh T, et al. An epigenetic trap stabilizes singular olfactory receptor expression. Cell. 2013; 154(2):325-336.

[17]Rickels R, Shilatifard A. A histone modifier's ill-gotten copy gains. Cell. 2013;154(3):477-479.

[18]Zhao W, Li Q, Ayers S, et al. Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell. 2013;152(5):1037-1050.

[19]Hakim O, Misteli T. SnapShot: Chromosome confirmation capture. Cell. 2012;148(5):1068.e1-2.

[20]Zhong FL, Batista LF, Freund A, et al. TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell. 2012;150(3):481-494.

[21]Chou J, Lin JH, Brenot A, et al. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013; 15(2):201-213.

[22]Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15(6): 546-554.

[23]Wang D, Zhang Z, O'Loughlin E, et al. MicroRNA-205 controls neonatal expansion of skin stem cells by modulating the PI(3)K pathway. Nat Cell Biol. 2013;15(10):1153-1163.

[24]Minoda A, Saitoh S, Takahashi K, et al. BAF53/Arp4 homolog Alp5 in fission yeast is required for histone H4 acetylation, kinetochore-spindle attachment, and gene silencing at centromere. Mol Biol Cell. 2005;16(1):316-327.

[25]Vega RB, Matsuda K, Oh J, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell. 2004;119(4):555-566.

[26]Schroeder TM, Kahler RA, Li X, et al. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem. 2004;279(40): 41998-42007.

[27]Westendorf JJ. Histone deacetylases in control of skeletogenesis. J Cell Biochem. 2007;102(2):332-340.

[28]Westendorf JJ, Zaidi SK, Cascino JE, et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 2002;22(22): 7982-7992.

[29]Kang JS, Alliston T, Delston R, et al. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J. 2005;24(14):2543-2555.

[30]Westendorf JJ. Transcriptional co-repressors of Runx2. J Cell Biochem. 2006;98(1):54-64.

[31]Lee HW, Suh JH, Kim AY, et al. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol. 2006;20(10):2432-2443.

[32]Thompson DD, Simmons HA, Pirie CM, et al. FDA Guidelines and animal models for osteoporosis. Bone. 1995;17(4 Suppl): 125S-133S.

[33]Kim JL, Kim YH, Kang MK, et al. Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis. Biomed Res Int. 2013; 2013: 919374.

[34]Ma B, Li X, Zhang Q, et al. Metabonomic profiling in studying anti-osteoporosis effects of strontium fructose 1,6-diphosphate on estrogen deficiency-induced osteoporosis in rats by GC/TOF-MS. Eur J Pharmacol. 2013;718(1-3): 524-532.

[35]Miyauchi Y, Sato Y, Kobayashi T, et al. HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A. 2013;110(41):16568-16573.

[36]Rossini M, Lello S, Sblendorio I, et al. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Des Devel Ther. 2013;7:601-610.

[37]Yang N, Wang G, Hu C, et al. Tumor necrosis factor α suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis. J Bone Miner Res. 2013;28(3):559-573.

[38]Almeida M, Iyer S, Martin-Millan M, et al. Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013;123(1):394-404.

[39]Galea GL, Meakin LB, Sugiyama T, et al. Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β. J Biol Chem. 2013;288(13):9035-9048.

[40]Sapir-Koren R, Livshits G. Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation? Osteoporos Int. 2013;24(6):1771-1789.

[41]Song L, Zhao J, Zhang X, et al. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur J Pharmacol. 2013;714(1-3):15-22.

[42]Zirngibl RA, Chan JS, Aubin JE. Divergent regulation of the Osteopontin promoter by the estrogen receptor-related receptors is isoform- and cell context dependent. J Cell Biochem. 2013;114(10):2356-2362.

[43]Binder NB, Niederreiter B, Hoffmann O, et al. Estrogen-dependent and C-C chemokine receptor-2- dependent pathways determine osteoclast behavior in osteoporosis. Nat Med. 2009;15(4):417-424.

[44]Bonnelye E, Saltel F, Chabadel A, et al. Involvement of the orphan nuclear estrogen receptor-related receptor α in osteoclast adhesion and transmigration. J Mol Endocrinol. 2010;45(6):365-377.

[45]Crusodé de Souza M, Sasso-Cerri E, Cerri PS. Immunohistochemical detection of estrogen receptor beta in alveolar bone cells of estradiol-treated female rats: possible direct action of estrogen on osteoclast life span. J Anat. 2009;215(6):673-681.

[46]Pederson L, Kremer M, Foged NT, et al. Evidence of a correlation of estrogen receptor level and avian osteoclast estrogen responsiveness. J Bone Miner Res. 1997;12(5): 742-752.

[47]Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002;30(2):368-376.

[48]Almeida M, Iyer S, Martin-Millan M, et al. Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013;123(1):394-404.

[49]Bonnelye E, Aubin JE. An energetic orphan in an endocrine tissue: a revised perspective of the function of estrogen receptor-related receptor alpha in bone and cartilage. J Bone Miner Res. 2013;28(2):225-233.

[50]Ming LG, Chen KM, Xian CJ. Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling. J Cell Physiol. 2013;228(3):513-521.

[51]Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377 (6548):454-457.

[52]Sevetson B, Taylor S, Pan Y. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem. 2004;279(14):13849-13858.

[53]Lamour V, Detry C, Sanchez C, et al. Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem. 2007;282(50):36240- 36249.

[54]Nam HK, Liu J, Li Y, et al. Ectonucleotide pyrophosphatase/ phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation. J Biol Chem. 2011;286(45):39059-39071.

[55]Marulanda J, Gao C, Roman H, et al. Prevention of arterial calcification corrects the low bone mass phenotype in MGP-deficient mice. Bone. 2013;57(2):499-508.

[56]Lie DC, Colamarino SA, Song HJ, et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005; 437(7063):1370-1375.

[57]Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1): 11-26.

[58]Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179-192.

[59]Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A. 2005;102(9):3324-3329.

[60]Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23(7):351-363.

[61]Maroni P, Brini AT, Arrigoni E, et al. Chemical and genetic blockade of HDACs enhances osteogenic differentiation of human adipose tissue-derived stem cells by oppositely affecting osteogenic and adipogenic transcription factors. Biochem Biophys Res Commun. 2012;428(2):271-277.